scispace - formally typeset
A

Aamir Ahmad

Researcher at University of Alabama at Birmingham

Publications -  257
Citations -  15418

Aamir Ahmad is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Cancer & Cancer stem cell. The author has an hindex of 63, co-authored 251 publications receiving 13404 citations. Previous affiliations of Aamir Ahmad include Aligarh Muslim University & Hamad Medical Corporation.

Papers
More filters
Journal ArticleDOI

Coinage Metal Complexes Against Breast Cancer

TL;DR: This review takes stock of the latest developments in the field of coinage metal anticancer drugs with an emphasis on their biological and mechanistic aspects.
Journal ArticleDOI

3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.

TL;DR: Inactivation of survivin by DIM enhanced the therapeutic efficacy of Taxotere in prostate cancer in general, which could be useful for the treatment of HRPC and metastatic prostate cancer.
Journal ArticleDOI

Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells

TL;DR: This study is the first to investigate the copper-mediated anticancer mechanism of plumbagin in human cancer cells and these properties could be further explored for the development of anticancer agents with higher therapeutic indices, especially for skin cancer.
Journal ArticleDOI

Erlotinib resistance in lung cancer: current progress and future perspectives.

TL;DR: Evidently, new chemotherapy strategies are desperately needed in order to better treat lung cancer patients, and current research is investigating alternative treatment plans to enhance the chemotherapy that is already offered.
Journal ArticleDOI

Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells.

TL;DR: The results establish a pleiotropic activity of HT against these oncogenic signaling pathways against Castration-resistant prostate cancers, which support further testing of HT for prostate cancer therapy.